{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-162620","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2026-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.721305+00:00","generated_at":"2026-05-15T05:20:25.926080+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Prelude Therapeutics presents preclinical data for PRT13722 KAT6A degrader at AACR 2026, plans IND mid-2026","bullets":["PRT13722 is a first-in-class, orally bioavailable, potent and highly selective KAT6A degrader for HR+/HER2- breast cancer.","Preclinical data show durable complete tumor regressions in xenograft models at well-tolerated doses as monotherapy.","PRT13722 demonstrated improved preclinical hematological safety profile compared to prifetrastat.","PRT13722 showed synergistic activity with endocrine therapy, CDK4/6 inhibitors, and PI3Kα inhibitors.","IND filing expected in mid-2026; Phase 1 study initiation planned for second half of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-162620","json":"https://secwatch.observer/filing/0001193125-26-162620.json","markdown":"https://secwatch.observer/filing/0001193125-26-162620.md","text":"https://secwatch.observer/filing/0001193125-26-162620.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526162620/0001193125-26-162620-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526162620/d135229d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T05:20:25.926080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}